Kerendia ™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
The European Commission granted approval for a label extension for Kerendia™ (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pharmaceuticals | Study | Urology & Nephrology